` OBD (Oxford Biodynamics PLC) vs FTSE All Share Index Comparison - Alpha Spread

OBD
vs
F
FTSE All Share Index

Over the past 12 months, OBD has outperformed FTSE All Share Index, delivering a return of -39% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
OBD vs FTSE All Share Index

Loading
OBD
FTSE All Share Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
OBD vs FTSE All Share Index

Loading
OBD
FTSE All Share Index
Difference
www.alphaspread.com

Performance By Year
OBD vs FTSE All Share Index

Loading
OBD
FTSE All Share Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Oxford Biodynamics PLC vs Peers

FTSE All Share Index
OBD
TMO
DHR
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Oxford Biodynamics PLC
Glance View

Oxford BioDynamics Plc is a biotechnology company, which engages in the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The firm is engaged in advancing personalized healthcare by developing and commercializing medicine tests for life-changing diseases. The company has developed a three dimensional (3D) genomic biomarker platform, EpiSwitch, which builds molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a range of indications. The platform discovers, evaluates, validates and monitors of biomarkers known as chromosome conformation signatures (CCSs). CCSs provides a compelling, stable framework from which changes in the regulation of a genome can be analyzed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities. EpiSwitch supports precision medicine initiatives, including prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring.

OBD Intrinsic Value
0.24 GBX
Overvaluation 18%
Intrinsic Value
Price
Back to Top